Polgreen, Philip M
Mayo Clinic
Division of Infectious Diseases, Carver College of Medicine University of Iowa, Iowa City, Iowa, USA.
Citations 2
Positron Emission Tomography/Computed Tomography in Cardiac Implantable Electronic Device Infections: Insights From the Emerging Infections Network
McHugh, Jack , Cuervo, Guillermo, Abu-Zeinah, Khalid , Beekmann, Susan E. , Polgreen, Philip M. , Deshmukh, Abhishek J, Johnson, G B, Saleh, Omar M Abu, Baddour, L M, Baddour, Larry M. , Johnson, Geoffrey B. , Cuervo, Guillermo , Chesdachai, Supavit , McHugh, Jack , Cuervo, Guillermo , Abu-Zeinah, Khalid , Beekmann, Susan E , Polgreen, Philip M , Deshmukh, Abhishek J , Johnson, Geoffrey B , Abu Saleh, Omar , DeSimone, Daniel C , Baddour, Larry , Chesdachai, Supavit , Deshmukh, Abhishek , Saleh, Omar Abu , DeSimone, Daniel C.
Open Forum Infectious Diseases | March 3, 2026 | Volume: 13 | Issue: 3 | Pages: No page available
Abstract The practice patterns of fluorine 18–labeled fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG PET/CT) use in cardiac implantable electronic device infection remain undefined. Among 258 Emerging Infections Network respondents, 69% reported never or rarely using [18F] FDG PET/CT. Limited access and insurance barriers were the most common obstacles.
Partial Oral Therapy for Infective Endocarditis Among Adult Infectious Diseases Physicians in the United States: An Emerging Infections Network Survey
McHugh, Jack , Baddour, Larry M. , Chesdachai, Supavit , Polgreen, Philip M. , Wilson, Walter R., DeSimone, Daniel C. , McHugh, Jack , Polgreen, Philip M , DeSimone, Daniel C , Baddour, Larry , Chesdachai, Supavit , Beekmann, Susan E.
Open Forum Infectious Diseases | September 19, 2025 | Volume: 12 | Issue: 9 | Pages: No page available
Abstract Background Recent clinical trial evidence supports broader use of partial oral therapy (POT) for infective endocarditis (IE), yet real-world uptake in the U.S. has not been investigated. Methods Adult infectious diseases (ID) physician members of the Infectious Diseases Society of America Emerging Infections Network were surveyed in April–May 2025. A 10-item instrument captured frequency of POT, organism-specific influence, decision factors, barriers, and facilitators. Results Among 1531 members, 516 (34%) responded; 452 (88%) of them managed IE. POT was uncommon: 16% never used, 53% used in ≤10% of cases, and only 10% used in >25% of patients. Frequent POT rose with caseload (23% in physicians treating >50 IE cases year vs ≤9% in lower-volume groups, P < .001) and with fewer years in clinical practice (13% in <5 yrs vs 5% in ≥25 yrs, P = .013). Comfort with POT depended on the pathogen: 66% were comfortable switching for Streptococcus spp., 52% for Gram-negative bacilli, 19% for methicillin-resistant Staphylococcus aureus. Three quarters of those who used POT finished with a single agent. In people who inject drugs, 34% of physicians often or always considered an oral regimen. Availability of an active oral agent (75%) and the pathogen involved (69%) were the leading decision drivers; principal barriers were fear of relapse (72%), adherence concerns (53%), and insufficient evidence (48%). Respondents most desired clearer guidelines (75%) and additional data (71%). Conclusions U.S. adult ID physicians adopt POT for IE sparingly. Updated IE treatment guidelines, additional clinical trial data, and broader access to complex outpatient antimicrobial therapy services may facilitate wider adoption.